TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07803783: A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Duct

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 320 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07803783 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07803783 Rescue Dossier →